BTX

Stats

Summary

Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to advance therapies using leading edge gene editing/cell therapy technology through its option agreements with Factor Bioscience and Novellus. Brooklyn’s most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.

Market Cap: 12.1 Million

Primary Exchange: NASDAQ

Website: brooklynitx.com

Shares Outstanding: 58.8 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.5916244111100661

Sector: Information

Industry: Television Broadcasting

Ethical Flags

Longest drawdown: 1614 trading days

From: 2015-04-23 To: 2021-04-05

Lowest Point:

Ex-Date	Payment Date	Record Date	Declared Date	Amount	Flag	Dividend Type	Qualified	Indicated

Ex-Date	Declared Date	Record Date	Payment Date	Ratio	To Factor	For Factor